Premium
Extra‐glycaemic properties of empagliflozin
Author(s) -
Solini Anna
Publication year - 2016
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.2666
Subject(s) - empagliflozin , tolerability , type 2 diabetes , medicine , canagliflozin , diabetes mellitus , overweight , dapagliflozin , transporter , pharmacology , insulin , obesity , endocrinology , intensive care medicine , adverse effect , chemistry , biochemistry , gene
Summary Type 2 diabetes is a complex and multifaceted disease requiring an individualized approach. A special attention, in treating the patients, should be devoted to the presence of comorbidities like overweight or obesity and arterial hypertension. Among the available anti‐hyperglycaemic agents, several are associated with side effects like hypoglycaemia and weight gain. An increasing interest is reported in sodium‐glucose co‐transporter‐2 inhibitors, a relatively novel class of glucose‐lowering drugs that act independently of insulin, provide benefits beyond glucose‐lowering actions and show a better tolerability compared with traditional medications for type 2 diabetes. This review tries to offer a balanced view on the main extra‐glycaemic effects of empagliflozin, also mentioning clinical data obtained with other sodium‐glucose co‐transporter‐2 inhibitors; the role of the proximal tubule in the pathophysiology of diabetic nephropathy and the potential nehroprotection exerted by this compound are also briefly discussed. Copyright © 2015 John Wiley & Sons, Ltd.